Background and Objectives: Substance use disorders (SUDs) affect millions worldwide. Despite increasing drug use, treatment options remain limited. Psychedelic-assisted therapy (PAT), integrating psychedelic substances with psychotherapy, offers a promising alternative by addressing underlying neural mechanisms. Materials and Methods: This review’s purpose is to investigate the current understanding of psychedelic therapy for treating SUDs, including tobacco, alcohol, and drug addiction. The systematic review approach focused on clinical trials and randomized controlled trials conducted from 2013 to 2023. The search was performed using PubMed, Google Scholar, and Consensus AI, following PRISMA guidelines. Studies involving psychedelics like LSD, psilocybin, ibogaine, and ayahuasca for treating various addictions were included, excluding naturalistic studies and reviews. Results: Our results highlight the key findings from 16 clinical trials investigating psychedelic therapy for SUDs. Psychedelics like psilocybin and ayahuasca showed promise in reducing alcohol and tobacco dependence, with psilocybin being particularly effective in decreasing cravings and promoting long-term abstinence. The studies revealed significant improvements in substance use reduction, especially when combined with psychotherapy. However, the variability in dosages and study design calls for more standardized approaches. These findings emphasize the potential of psychedelics in SUD treatment, though further large-scale research is needed to validate these results and develop consistent protocols. Conclusions: This research reviewed the past decade’s international experience, emphasizing the growing potential of psychedelic therapy in treating SUDs pertaining to alcohol, tobacco, and cocaine dependence. Psychedelics such as psilocybin and ketamine can reduce cravings and promote psychological well-being, especially when combined with psychotherapy. However, regulatory barriers and specialized clinical training are necessary to integrate these therapies into mainstream addiction treatment safely. Psychedelics offer a promising alternative for those unresponsive to conventional methods.

Background and Objectives: Addiction and relapse prevention of alcohol and drug users is a real problem globally. Studies report different pharmacological and non-pharmacological methods in preventing relapse with varying ranges of results across the time of relapse. The study aims to identify novel insights into relapse prevention for high-risk alcohol and drug addiction across diverse global populations, ages, and intervention types during detoxification. Materials and Methods: This meta-analysis followed PRISMA guidelines, synthesizing 12 eligible studies published between 2013 and 2023, totaling 2162 participants. Data extraction and statistical analysis were conducted using Python-based libraries. Regression models were applied to examine the influence of age, gender, and intervention type on the mean relapse period. Results: 12 studies with 2162 patients were identified. These studies examined substances, interventions, and demographics, highlighting male predominance in addictive behaviors. OSL regression assessed factors influencing mean relapse periods, finding that age explained 44.2% of the variability (p = 0.0131). The male percentage explained 17.1%, but the significance was inconclusive, as was the female gender’s negligible impact (14.7% variability). Intervention types significantly influenced relapse periods, supported by a large F-statistic. Linear regression showed no consistent trend in relapse periods, with declining research post-2018. Forest plots indicated disparities in relapse periods due to treatment or methodology. Most participants were high-risk drug users, though alcohol use was also represented. A declining trend in publication rates after 2018 was observed. Conclusions: Age and intervention type were identified as key factors influencing relapse duration, while gender and substance-specific effects require further study. The findings underscore the need for more targeted, gender-sensitive, and context-aware treatment strategies.